1. Home
  2. VLY vs TGTX Comparison

VLY vs TGTX Comparison

Compare VLY & TGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Valley National Bancorp

VLY

Valley National Bancorp

BUY

Current Price

$13.51

Market Cap

7.2B

Sector

Finance

ML Signal

BUY

Logo TG Therapeutics Inc.

TGTX

TG Therapeutics Inc.

HOLD

Current Price

$38.65

Market Cap

6.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
VLY
TGTX
Founded
1927
1993
Country
United States
United States
Employees
3675
N/A
Industry
Major Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
7.2B
6.0B
IPO Year
N/A
2008

Fundamental Metrics

Financial Performance
Metric
VLY
TGTX
Price
$13.51
$38.65
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
13
5
Target Price
$14.65
$49.80
AVG Volume (30 Days)
4.6M
2.1M
Earning Date
04-23-2026
05-04-2026
Dividend Yield
3.31%
N/A
EPS Growth
N/A
1746.67
EPS
N/A
0.12
Revenue
N/A
$2,785,000.00
Revenue This Year
$23.58
$49.08
Revenue Next Year
$8.51
$26.69
P/E Ratio
$13.14
$322.96
Revenue Growth
N/A
N/A
52 Week Low
$8.36
$25.37
52 Week High
$14.12
$44.65

Technical Indicators

Market Signals
Indicator
VLY
TGTX
Relative Strength Index (RSI) 56.82 52.03
Support Level $13.22 $33.05
Resistance Level $13.93 $44.65
Average True Range (ATR) 0.29 1.90
MACD -0.02 -0.42
Stochastic Oscillator 70.05 38.19

Price Performance

Historical Comparison
VLY
TGTX

About VLY Valley National Bancorp

Valley National Bancorp is a bank holding company that offers a full suite of national and regional banking solutions through various commercial, private banking, retail, insurance, and wealth management financial services products. It provides personalized service and customized solutions to assist its customers with their financial service needs. The group also offers niche financial services, including loan and deposit products for homeowners associations, cannabis-related business banking, and venture banking, which offers nationally. It manages its business operations under operating segments consisting of Consumer Banking; Commercial Banking; and Treasury and Corporate Other. The group generates the majority of its revenue from the Commercial Banking Segment.

About TGTX TG Therapeutics Inc.

TG Therapeutics Inc is a fully integrated, commercial-stage biotechnology company focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. In addition to a research pipeline, it has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) to treat adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, as well as approval from several regulatory agencies outside of the U.S. Its pipeline includes UBLITUXIMAB, SUB-Q UBLITUXIMAB, and AZER-CEL. Geographically, it generates a majority of its revenue selling BRIUMVI in the United States, with the rest coming from the international market.

Share on Social Networks: